Active substanceImipenem + CilastatinImipenem + Cilastatin
Similar drugsTo uncover
  • Aquapenem
    powder in / in 
  • Grimipenem®
    powder d / infusion 
    PREBAND PFC, LLC     Russia
  • Imipenem + cilastatin
    powder in / in 
    KRASFARMA, JSC     Russia
  • Imipenem and Cilastatin Jodas
    powder d / infusion 
  • Imipenem and Cilastatin Spencer
    powder d / infusion 
    Spencer Pharma UK Limited     United Kingdom
  • Imipenem + Cilastatin
    powder d / infusion 
    HIMFARM, JSC     Kazakhstan
  • Imipenem + Cilastatin
    powder d / infusion 
    VELFARM, LLC     Republic of San Marino
  • Imipenem + Cilastatin-Vial
    powder d / infusion 
    VIAL, LLC     Russia
  • Imipenem / Cilastatin Kabi
    powder d / infusion 
  • Tienam®
    powder d / infusion 
    Merck Sharp and Doum B.V.     Netherlands
  • Tiepenem
    powder in / in 
       
  • Cilapenem
    powder in / in 
    BELMEDPREPARATY, RUP     Republic of Belarus
  • Cilapenem
    powder d / infusion 
    BELMEDPREPARATY, RUP     Republic of Belarus
  • Cilaspin
    powder d / infusion 
  • Dosage form: & nbspPowder for suspension for intramuscular administration
    Composition:Composition per one bottle: active substances: imipenem monohydrate (in terms of imipenem) - 0.250 g or 0.500 g, cilastatin sodium (in terms of cilastatin) - 0.250 g or 0.500 g.
    Description:Powder from white to yellowish color.Freshly prepared suspension is a homogeneous suspension of white or slightly yellow color.
    Pharmacotherapeutic group:antibiotic-carbapenem + dehydropeptidase inhibitor
    ATX: & nbsp

    J.01.D.H.51   Imipenem and dehydropeptidase inhibitor

    Pharmacodynamics:
    Beta-lactam antibiotic of broad spectrum of action. Suppresses the synthesis of the bacterial cell wall and has a bactericidal effect against a wide range of gram-positive and gram-negative microorganisms, aerobic and anaerobic. Imipenem - a derivative of tienamycin, belongs to the group of carbapenems. Cilastatin sodium inhibits dehydropeptidase, an enzyme that metabolizes imipenem in the kidneys, which significantly increases the concentration of unchanged imipenem in the urinary tract. Cilastin does not have its own antibacterial activity, does not inhibit beta-lactamase bacteria.
    Cilapenem is active against Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus faecalis and Bacteroides fragilis. Resistant to degradation by bacterial beta-lactamase, which makes it effective against many microorganisms, such as Pseudomonas aeruginosa, Serratia spp. and Enterobacter spp., which are resistant to most beta-lactam antibiotics.The antibacterial spectrum includes virtually all clinically relevant pathogens. It is active against gram-negative aerobic bacteria: Achromobacter spp., Acinetobacter spp. (formerly Mima-Herellea), Aeromonas hydrophila, Alcaligenes spp., Bordetella bronchicanis, Bordetella bronchiseptica, Bordetella pertussis, Brucella melitensis, Campylobacter spp., Capnocytophaga spp., Citrobacter spp. (including Citrobacter diversus, Citrobacter freundii), Eikenella corrodens, Enterobacter spp. (Including Enterobacter aerogenes, Enterobacter agglomerans, Enterobacter cloacae), Escherichia coli, Gardnerella vaginalis, Haemophilus ducreyi, Haemophilus influenzae (including strains forming beta-lactamase), Haemophilus parainfluenzae, Hafiiia alvei, Klebsiella spp (incl . Klebsiella oxytoca, Klebsiella ozaenae, Klebsiella pneumoniae), Moraxella spp., Morganella morganii (formerly Proteus morganii), Neisseria gonorrhoeae (including strains forming penicillinase), Neisseria meningitidis, Yersinia spp. (formerly Pasteurella), incl. Yersinia multocida, Yersinia enterocolitica, Yersinia pseudotuberculosis; Plesiomonas shigelloides, Proteus spp. (including Proteus mirabilis, Proteus vulgaris), Providencia spp. (including Providencia alcalifaciens, Providencia rettgeri (formerly Proteus rettgeri), Providencia stuartii), Pseudomonas spp. (including Pseudomonas aeruginosa, Pseudomonas fluorescens, Pseudomonas pseudomallei, Pseudomonas putida, Pseudomonas stutzerf), Salmonella spp. (including Salmonella typhi), Serratia spp. (including Serratia marcescens, Serratia proteamaculans), Shigella spp., Gram-positive aerobic bacteria: Bacillus spp., Enterococcus faecalis, Erysipelothrix rhusiopathiae, Listeria monocytogenes, Nocardia spp., Pediococcus spp., Staphylococcus aureus (including strains forming penicillinase), Staphylococcus epidermidis (including strains forming penicillinase), Staphylococcus saprophytics, Streptococcus agalactiae, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus group C, Streptococcus group G, greening streptococci including alpha and gamma hemolytic strains); Gram-negative anaerobic bacteria: Bacteroides spp. (Including Bacteroides distasonis, Bacteroides fragilis, Prevotella melaninogenica (formerly Bacteroides melaninogenicus), Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus), Bilophila wadsworthia, Fusobacterium spp including (Fusobacterium necrophorum, Fusobacterium nucleatum), Porphyromonas asaccharolytica (formerly Bacteroides asaccharolyticus), Prevotella bivia (formerly
    Bacteroides bivius), Prevotella disiens (formerly Bacteroides disiens), Prevotella intermedia (formerly Bacteroides intermedius), Veillonella spp .; Gram-positive anaerobic bacteria: Actinomyces spp., Bifidobacterium spp., Clostridium spp. (including Clostridium perfringens), Eubacter spp., Lactobacillus spp., Microaerophilic streptococcus, Mobiluncus spp., Peptococcus spp., Peptostreptococcus spp., Propionibacterium spp. (including Propionibacterium acne); other microorganisms: Mycobacterium fortuitum, Mycobacterium smegmatis. Some Staphylococcus spp.(resistant to methicillium), Streptococcus spp. (Group D), Stenotrophomonas maltophilia, Enterococcus faecium and some strains of Pseudomonas cepacia are insensitive to imipenem. Effective against many infections caused by bacteria, resistant to cephalosporins, aminoglycosides, penicillins. In vitro acts synergistically with aminoglycosides against some strains of Pseudomonas aeruginosa.

    Pharmacokinetics:With intramuscular injection, the bioavailability of imipenem is 95%, cilastatin 75%. The connection with plasma proteins of imipenem is 20%, cilastatin is 40%. Stax (maximum concentration) of imipenem for intramuscular injection of 500 or 750 mg is 10 and 12 μg / ml, respectively. The cilastatin stasis with intramuscular injection of 500 or 750 mg is 24 and 33 μg / ml, respectively. Quickly and well distributed in most tissues and body fluids. The highest concentrations are achieved in pleural effusion, peritoneal and interstitial fluids and reproductive organs. In low concentrations it is found in the cerebrospinal fluid. The volume of distribution in adults is 0,23-0,31 l / kg, in children 2-12 years - 0,7 l / kg, in newborns - 0,4-0,5 l / kg. Blocking tubular secretion of imipenem with cilastatin results in inhibition of its renal metabolism and accumulation in the urine in unchanged form.Cilastatin is metabolized to the N-acetyl compound. With intramuscular injection, the half-life of imipenem is 2-3 hours. It is mainly excreted by the kidneys (70-76% for 10 hours) by glomerular filtration (2/3) and active tubular secretion (1/3); 1-2% is excreted with bile and 20-25% - extracellular path (mechanism is unknown). Quickly and effectively (73-90%) is excreted by hemodialysis (as a result of a 3-hour session of intermittent hemofiltration, 75% of the dose is removed).
    Indications:
    Infectious-inflammatory diseases caused by sensitive microorganisms: lower respiratory tract infections caused by streptococcus pneumoniae, haemophilus influenzae; intra-abdominal infections caused by Group D streptococci, including enterococcus faecalis, streptococcus spp. Groups of viridians, escherichia coli, klebsiella pneumoniae, pseudomonas aeruginosa, bacteroides spp., Including b. Fragilis, peptostreptococcus spp., Fusobacterium spp .; gynecological infections caused by Group D streptococci, including enterococcus faecalis, escherichia coli, klebsiella pneumoniae, bacteroides intermedius, peptostreptococcus spp .; skin and subcutaneous tissue infections caused by staphylococcus aureus, including penicillinase-producing strains, streptococcus pyogenes, group d streptococci, including enterococcus faecalis, acinetobacter spp., citrobacter spp., enterobacter cloacae, escherichia coli, klebsiella pneumoniae, pseudomonas aeruginosa, bacteroides spp. , including b. Fragilis.

    Contraindications:
    Hypersensitivity (including carbapenems and other beta-lactam antibiotics), pregnancy, children under 12 years of age,chronic renal failure (CRF) (creatinine clearance (CC) less than 20 ml / min); for the prepared suspension using lidocaine hydrochloride as a solvent - hypersensitivity to local amide anesthetics, as well as in patients with severe shock or disturbances of intracardiac conductivity.
    Carefully:Pseudomembranous colitis, CRF (patients with creatinine clearance less than 70 ml / min / 1.73 m2), central nervous system diseases, lactation period, elderly age, convulsions in the anamnesis, high convulsive readiness, anticonvulsant therapy of valproic acid (decreased effectiveness of therapy); diseases of the gastrointestinal tract in the anamnesis.
    Pregnancy and lactation:During pregnancy, the drug is used only for "vital" indications, when the expected benefit of the treatment justifies the potential risk to the fetus. Imipenem is found in human breast milk. If the use of Cilapenem is considered necessary, then breastfeeding of the baby should be stopped.
    Dosing and Administration:Intramuscularly, deep into large muscles. This route of administration can be used as an alternative to intravenous forma drug for the treatment of infections in which intramuscular administration is preferred. The dosage form for intramuscular administration should not be used for intravenous infusions and vice versa. The drug is administered in a dose of 500-750 mg (based on imipenem) every 12 hours, depending on the severity of the infection, the sensitivity of pathogenic microorganisms and the patient's condition (Table 1).

    Table 1. The dosage regimen of Cilapenem for intramuscular injection
    adult patients with normal renal function and weighing> 70 kg

    Localization of infection

    Severity of infection

    Dose

    Lower respiratory tract

    Skin and soft tissue Gynecological infections

    Light / moderate

    500 or 750 mg every 12 hours, depending on the severity of the infection

    Intraabdominal

    Light / moderate

    750 mg every 12 hours


    The maximum daily dose is not more than 1500 mg. With intramuscular administration of cilapenem, patients with SC greater than 20 mL / min / 1.73 m2 of dosing regimen adjustment it takes. The safety of intramuscular injection in patients with SC less
    20 ml / min / 1.73 m2, as well as in children under 12 years of age has not been studied.
    Treatment should continue for 2 more days after the resolution of the symptoms of the disease. The efficacy and safety of treatment after 14 days of use has not been studied.
    Powder for the preparation of the suspension is mixed with 2 ml of a 1% solution of lidocaine hydrochloride (without epinephrine), water for injection or 0.9% sodium chloride solution until a uniform suspension (white or slightly yellow). Use only freshly prepared suspension.

    Side effects:
    The incidence of side effects is given in the following gradation: very often (> 1/10); often (> 1/100, <1/10); infrequently (> 1/1000, <1/100); rarely (> 1/10000, <1/1000); very rarely (<1/10000), including individual messages.
    From the nervous system: not often - drowsiness, myoclonia, mental disorders, hallucinations, confusion, epileptic seizures; rarely - hearing loss; very rarely - headache, ringing in the ears; encephalopathy, paresthesia, asthenia.
    From the sense organs: rarely - hearing loss, ringing in the ears, perversion of taste.
    From the urinary system: rarely - oliguria, anuria, polyuria, proteinuria, the appearance of protein, erythrocytes, leukocytes, urinary cylinders, increased bilirubin concentration and a change in urine color (safe and should not be mistaken for hematuria), kidney failure. The effect of the drug in changes in renal function is difficult to assess, since there are usually other factors,predisposing to prerenal azotemia or impaired renal function.
    From the gastrointestinal tract: often - nausea, vomiting, diarrhea; rarely - hypertrophy of the papillae of the tongue, pain in the pharynx, abdominal pain, glossitis, hypersalivation, dental pigmentation and / or language, pseudomembranous enterocolitis (clinically significant as in the case of other broad-spectrum antibacterial drugs) (see "With caution" ), both during and after the completion of treatment, hepatitis; very rarely - gastroenteritis, fulminant hepatitis, hepatic insufficiency, jaundice.
    From the respiratory system: very rarely - a feeling of discomfort in the chest, shortness of breath, hyperventilation, pain in the thoracic spine, burning behind the sternum.
    From the side of the cardiovascular system: not often - lowering blood pressure; rarely: palpitation, tachycardia.
    Laboratory indicators:
    - biochemical: often - increased activity of "liver" transaminases and alkaline phosphatase; infrequently - hyperbilirubinemia, hypercreatininaemia, increased concentration of urea nitrogen; direct positive Coombs test;
    - hematological: infrequently - pancytopenia, thrombocytopenia, thrombocytosis, leukopenia, neutropenia, leukocytosis, monocytosis, lymphocytosis, an increase in the number of basophils, a decrease in hemoglobin and hematocrit, an increase in prothrombin time; often - eosinophilia, rarely - agranulocytosis; very rarely - oppression of the red bone marrow function, hemolytic anemia.
    Against the background of granulocytopenia, more frequent episodes of nausea and vomiting are noted. Electrolyte balance: infrequent - decrease in serum sodium and chloride concentration, increase in potassium concentration.
    Allergic reactions: often - skin rash, itching; infrequently - hives; rarely - multiforme exudative erythema (including Stevens-Johnson syndrome), angioedema, toxic epidermal necrolysis, exfoliative dermatitis, fever; very rarely - anaphylactic reactions, cyanosis, hyperhidrosis.
    Local reactions: often - skin hyperemia, thrombophlebitis; infrequently - pain at the injection site; erythema at the injection site, infection at the injection site.
    Other: very rarely - candidiasis, itching of the vagina, a taste disorder, polyarthralgia.

    Overdose:
    Symptoms: specific symptoms are absent. When an overdose of the drug may increase dose-dependent side effects.
    Treatment: There is no specific information on the treatment of an overdose with Cilapenem. Cilapenem undergoes hemodialysis. However, the effectiveness of this procedure with an overdose is unknown.

    Interaction:
    Pharmaceutically incompatible with lactic acid salt, other antibacterial drugs. With simultaneous application with penicillins and cephalosporins, a cross-allergy is possible; shows antagonism towards other beta-lactam antibiotics (penicillins, cephalosporins and monobactams). Ganciclovir increases the risk of developing generalized seizures, concomitant administration is not recommended unless the potential benefits exceed the possible risk.
    Administration of cilapenem is associated with a decrease in serum valproic acid concentration with an associated risk of increased seizure activity (cases reported in clinical practice), therefore it is recommended to monitor the serum concentration of valproic acid during the treatment period.Drugs that block tubular secretion, slightly increase the concentration in the plasma and the half-life of imipenem (if high concentrations of imipenem are required, it is not recommended to use these medicines at the same time).

    Special instructions:
    Application in pediatric practice:
    The efficacy and safety of imipenem / cilastatin when administered intramuscularly to children younger than 12 years of age is not established.
    Application in elderly patients: the efficacy and safety of imipenem / cilastatin when administered intramuscularly in elderly people over the age of 65 do not differ from those in younger patients. However, taking into account the reduced functions of the cardiovascular system, liver, kidneys, as well as the presence of concomitant diseases and concomitant drug therapy, caution should be exercised in choosing a dose, adhering to the lower limits of the recommended doses. It is advisable to monitor the excretory function of the kidneys.
    Do not mix in one syringe with other antibiotics, while allowing simultaneous - isolated administration with other antibiotics. Not recommended for the treatment of meningitis.Stains urine in a reddish color. Before the start of therapy, a thorough anamnesis should be made about the previous allergic reactions to beta-lactam antibiotics. People with a history of gastrointestinal disease (especially colitis) have an increased risk of developing pseudomembranous colitis.
    Therapy with antiepileptic drugs in patients with brain injuries or fits in the anamnesis should continue throughout the treatment period with the drug (to avoid side effects from the central nervous system).
    When using the drug, both in the background of taking, and after 2-3 weeks. after discontinuation of treatment, the development of diarrhea caused by Clostridium difficile (pseudomembranous colitis) is possible. In mild cases, it is sufficient to discontinue treatment and apply ion-exchange resins (colestramine, colestipol), in severe cases, compensation for loss of fluid, electrolytes and protein, the appointment of vancomycin, bacitracin or metronidazole. Do not use drugs that inhibit the intestinal motility.
    Effect on the ability to drive transp. cf. and fur:Given the potential for side effects on the background of treatment with the drug Tsilapenem, you need to take extra care when driving and working with mechanisms.
    Form release / dosage:Powder for the preparation of suspension for intramuscular injection 0.25 g + 0.25 g and 0.5 g + 0.5 g.
    Packaging:
    For 0.25 g imipenem + 0.25 g cilastatin or 0.5 g imipenem + 0.5 g cilastatin powder in bottles with a capacity of 10 ml. Each bottle, together with the instructions for use, is placed in a pack of cardboard.
    Packing for hospitals: 40 bottles with an equal number of instructions for use are placed in a box of cardboard

    Storage conditions:Store in a dark place at a temperature of no higher than 25 ° C. Keep out of the reach of children.
    Shelf life:
    Shelf life 2 years.
    Do not use after the expiration date printed on the package.
    Terms of leave from pharmacies:On prescription
    Registration number:LP-001273
    Date of registration:24.11.2011
    The owner of the registration certificate:BELMEDPREPARATY, RUP BELMEDPREPARATY, RUP Republic of Belarus
    Manufacturer: & nbsp
    BELMEDPREPARATY, RUP Republic of Belarus
    Information update date: & nbsp24.11.2011
    Illustrated instructions
      Instructions
      Up